GlassScriptPhysician profile
Melissa L Stenstrom
NPI 1477745255
$13,026.66
in general payments reported to CMS, 2019-2025
35 companies · $3,696 in 2025
The $3,696 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,448 · 2020: $1,416 · 2021: $1,542 · 2022: $1,323 · 2023: $1,563 · 2024: $2,039 · 2025: $3,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,940 · Education: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,939.50 |
| Education | $358.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,451.44 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Sun Pharmaceutical Industries INC. | $915.97 | 2019-2025 | Odomzo, Blu-U, Ilumya |
| Janssen Biotech, INC. | $890.10 | 2019-2025 | Tremfya |
| Genzyme Corporation | $884.60 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $795.18 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $782.91 | 2019-2025 | |
| Lilly USA, LLC | $653.32 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Pfizer INC. | $585.60 | 2019-2025 | |
| Ucb, INC. | $517.34 | 2019-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $376.49 | 2024-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $303.96 | 2020-2021 | |
| Dermavant Sciences, INC. | $260.14 | 2023-2024 | Vtama |
| Amgen INC. | $256.72 | 2020-2025 | Otezla |
| Galderma Laboratories, L.P. | $227.25 | 2019-2025 | Aklief, Nemluvio |
| Leo Pharma INC. | $222.57 | 2019-2023 | Adbry |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $215.79 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $211.90 | 2022-2025 | Sotyktu |
| Merz North America, INC. | $185.55 | 2019 | |
| Janssen Scientific Affairs, LLC | $174.90 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $170.23 | 2020-2025 | |
| Almirall LLC | $161.98 | 2019-2023 | Klisyri |
| Allergan, INC. | $134.25 | 2019-2022 | |
| Celgene Corporation | $114.11 | 2019 | |
| Botanix Sb INC | $82.18 | 2025 | Sofdra |
| Epi Health, LLC | $78.52 | 2019-2022 | |
| Organon LLC | $66.51 | 2024-2025 | Vtama |
| Genentech USA, INC. | $58.50 | 2019-2021 | |
| Verrica Pharmaceuticals INC. | $54.14 | 2025 | Ycanth |
| Biofrontera INC. | $38.83 | 2024-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Dusa Pharmaceuticals, INC. | $38.46 | 2019 | |
| Incyte Corporation | $36.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Taro Pharmaceuticals USA, INC. | $22.13 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $14.02 | 2022 | |
| Smith+Nephew, INC. | $13.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Stenstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.